Earnings ·
Belite Bio reported unaudited financial results for the second quarter ended June 30, 2026
BLTEBelite Bio, Inc
Belite Bio reported unaudited financial results for the second quarter ended June 30, 2026. The company holds $279.9 million in cash and equivalents alongside $500.1 million in investments. R&D expenses rose to $18.2 million from $11.0 million a year earlier, while SG&A increased to $16.7 million from $6.5 million due to team expansion and professional fees. The net loss widened to $28.4 million compared to $16.3 million in the prior-year period. A key corporate update is that the FDA accepted the New Drug Application for tinlarebant for Stargardt disease type 1 with Priority Review status, setting a PDUFA target action date of February 12, 2027. The company also presented additional positive secondary endpoint data from its Phase 3 DRAGON trial at the ASRS Annual Meeting. Belite Bio is a clinical-stage biotechnology company focused on developing novel therapeutics for degenerative retinal diseases.